Pharmaron and Vaccitech (NASDAQ: VACC) enter into a Strategic Partnership for the Development and cGMP Manufacturing Services for Adenoviral Vector programme

We are delighted to announce that we have entered into a Strategic Partnership for the Development and cGMP Manufacturing Services for Vaccitech’s Adenoviral Vector programme. Pharmaron will become a key part of Vaccitech’s manufacturing network to support novel T cell immunotherapeutics and vaccines from its proprietary ChAdOx1 viral vector platform.

The partnership began last year with the technology transfer of a Vaccitech proprietary manufacturing process into Pharmaron’s state-of-the-art Liverpool viral development and GMP manufacturing facilities. This will enable Pharmaron to support subsequent late-stage product development and manufacturing of Vaccitech’s innovative product pipeline.

Derek Ellison, VP Biologics Services Europe, Pharmaron’s Gene Therapy CDMO, commented, “I am delighted that Vaccitech plc, a company with proven, world-leading immunotherapeutic technology, has selected Pharmaron as the preferred strategic partner for their programmes. This is an important milestone as we continue to grow and expand our vaccine, gene therapy and biologic capabilities and capacities to serve our partners’ needs in these exciting, emerging therapies. Vaccitech have recognised our team’s depth of expertise, in both process and analytical services, including for process characterisation, our collaborative, flexible approach and our commitment to being the best possible partner. We will employ all of our global expertise and resources to ensure that we successfully support Vaccitech’s mission to bring life changing immunotherapeutics to patients”.

Media Contact Information: 

Ellen Cabral, Senior Marketing Director Tel: +1 617 901 2216,